IV hydration not beneficial in end stage cancer

In this trial of 129 patients with end stage cancer, they were randomized to IV hydration (1 liter a day) or control (100 cc a day), and found no difference between the groups in symptoms of dehydration, delirium, or fatigue, and no difference in survival. This randomized trial does not support the use of IV hydration in patients with end stage cancer (abstract).

Danielle Scheurer

Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.

Leave a Comment